The current study showed that pharmaceutical inhibition of PP2A with LB-100 in different murine tumour models induced MMR gene silencing and a MSI status, triggered neoantigen production, and enhanced infiltration of cytotoxic CD8+ lymphocytes into tumours, thereby synergistically improving their activity against tumour growth and enhancing survival. The gene discussed is CD8A; the disease is neoplasm.